DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER Drug Patent Profile

« Back to Dashboard

When do Dianeal Low Calcium W/dextrose 2.5% In Plastic Container patents expire, and when can generic versions of Dianeal Low Calcium W/dextrose 2.5% In Plastic Container launch?

Dianeal Low Calcium W/dextrose 2.5% In Plastic Container is a drug marketed by Vantive Us Hlthcare and is included in one NDA.

The generic ingredient in DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER is calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate profile page.

Summary for DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
DailyMed Link:	DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	NA
Yale University	NA
Iperboreal Pharma Srl	Phase 3

See all DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER clinical trials

Pharmacology for DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER

Drug Class	Blood Coagulation Factor Calculi Dissolution Agent Osmotic Laxative Phosphate Binder
Mechanism of Action	Magnesium Ion Exchange Activity Osmotic Activity Phosphate Chelating Activity Acidifying Activity
Physiological Effect	Increased Coagulation Factor Activity Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption Inhibition Small Intestine Fluid/Electrolyte Absorption Stimulation Large Intestine Fluid/Electrolyte Secretion

US Patents and Regulatory Information for DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vantive Us Hlthcare	DIANEAL LOW CALCIUM W/DEXTROSE 2.5% IN PLASTIC CONTAINER	calcium chloride; dextrose; magnesium chloride; sodium chloride; sodium lactate	SOLUTION;INTRAPERITONEAL	017512-013	Jul 11, 1990	AT	RX	Yes	No

Dianeal Low Calcium With Dextrose 2.5% in Plastic Container: Market Dynamics and Financial Trajectory

Last updated: November 6, 2026

DIANEAL Low Calcium with Dextrose 2.5% is a Baxter peritoneal dialysis solution used for continuous ambulatory peritoneal dialysis and automated peritoneal dialysis. Its market is mature, recurring and procedure-driven, with demand tied to the global prevalence of end-stage kidney disease, home-dialysis adoption, reimbursement policy and manufacturing reliability.

The product does not have a separately reported public revenue line. Its financial trajectory must be assessed through Baxter’s former Kidney Care business, now operated as Vantive following Baxter’s 2024 divestiture. Product-level patent barriers appear limited compared with pharmaceuticals, but sterile manufacturing, regulatory registrations, supply-chain qualification and customer switching costs create practical barriers to entry.

What is DIANEAL Low Calcium with Dextrose 2.5%?

DIANEAL Low Calcium with Dextrose 2.5% is a sterile peritoneal dialysis solution supplied in plastic containers. The active osmotic agent is dextrose at a 2.5% concentration. The low-calcium formulation is intended for patients requiring peritoneal dialysis fluid with reduced calcium content.

The product is used to remove excess fluid and metabolic waste through the peritoneal membrane. The 2.5% dextrose concentration provides greater ultrafiltration than lower-dextrose solutions, although repeated exposure can contribute to glucose absorption and metabolic effects.

Product attribute	Description
Brand	DIANEAL
Formulation	Low calcium with dextrose 2.5%
Dosage form	Sterile peritoneal dialysis solution
Container	Plastic container
Administration	Intraperitoneal
Primary use	Continuous ambulatory and automated peritoneal dialysis
Manufacturer historically associated with product	Baxter Healthcare
Current operating context	Kidney Care business divested by Baxter to Carlyle and operated as Vantive
Therapeutic category	Renal replacement therapy
Revenue disclosure	Not separately reported publicly

Dianeal products are generally sold through dialysis providers, hospitals, distributors and home-care channels. Purchasing decisions depend on a provider’s dialysis platform, transfer-set compatibility, delivery model and contract terms.

What is the FDA regulatory status of DIANEAL 2.5%?

DIANEAL is an FDA-regulated prescription dialysis product marketed as a sterile solution for peritoneal administration. Unlike a conventional oral drug, its commercial viability depends on the integrated product system: formulation, container, sterilization process, labeling, packaging and distribution controls.

The product’s regulatory risks are therefore concentrated in:

• Sterility assurance.
• Container-closure integrity.
• Particulate and endotoxin control.
• Formulation consistency.
• Manufacturing-site qualification.
• Product-change controls.
• Supply continuity.
• Adverse-event and product-quality reporting.

Peritoneal dialysis solutions are particularly sensitive to manufacturing interruptions because patients may require daily exchanges and cannot easily substitute an unqualified product. FDA enforcement activity involving dialysis products has historically focused on contamination, manufacturing deviations, labeling and supply reliability rather than clinical efficacy disputes.

How large is the peritoneal dialysis market?

Peritoneal dialysis is a minority but strategically important segment of global dialysis. Hemodialysis remains the dominant modality in most markets, but peritoneal dialysis has a lower infrastructure burden and can be administered at home.

Market demand is supported by:

1. Growth in end-stage kidney disease.
2. Greater use of home dialysis.
3. Government efforts to reduce in-center dialysis costs.
4. Patient preference for home treatment.
5. Expansion of dialysis capacity in emerging markets.
6. Increased use of automated peritoneal dialysis.

The United States has been a major policy driver. The 2019 Advancing American Kidney Health initiative established a federal objective of increasing home dialysis and kidney transplantation, although implementation has varied by provider, payer and patient population.[1]

Peritoneal dialysis demand is not directly equivalent to Dianeal demand. Patients may receive other Baxter solutions, including lower- or higher-dextrose formulations, icodextrin-based solutions such as EXTRANEAL, or competing products from Fresenius Medical Care and regional suppliers.

What drives demand for Dianeal Low Calcium 2.5%?

Demand is primarily volume-driven rather than innovation-driven.

Patient growth

The incidence of chronic kidney disease and end-stage kidney disease supports long-term dialysis utilization. The United States Renal Data System reported more than 800,000 people living with end-stage kidney disease in the United States in recent reporting periods, with dialysis accounting for the majority of treatment.[2]

Home-dialysis adoption

Peritoneal dialysis is performed at home, reducing dependence on dialysis-center capacity. Automated peritoneal dialysis can be attractive for patients seeking overnight treatment, although the treatment choice depends on clinical suitability, caregiver support, housing and reimbursement.

Formulation selection

The 2.5% dextrose concentration is selected when greater fluid removal is required than with 1.5% dextrose. It is not used identically across all exchanges. Clinicians may alternate concentrations based on the patient’s volume status and metabolic profile.

Recurring utilization

A patient receiving peritoneal dialysis may use multiple solution bags each day. This creates predictable recurring demand once a patient is established on therapy. The recurring model supports stable utilization but also increases the operational impact of shortages.

Provider contracts

Dialysis providers often standardize around a limited number of solution systems. A provider’s installed base, logistics network and training program can make conversion costly even when competing products are clinically substitutable.

What is the financial trajectory for DIANEAL?

Product-level financial data are not publicly disclosed. Baxter historically reported Kidney Care revenue at the segment level rather than breaking out individual Dianeal presentations.

The financial trajectory has four stages:

Period	Financial driver	Impact on Dianeal
Mature Baxter period	Stable dialysis utilization and recurring home-care demand	Broadly defensive revenue profile
2020-2023	Pandemic disruption, logistics pressure and inflation	Higher manufacturing and distribution costs
2024 divestiture	Sale of Baxter Kidney Care to Carlyle	Ownership transition and standalone cost restructuring
Post-divestiture Vantive period	Focused renal-care portfolio and operating efficiency	Potential margin improvement, but execution-dependent

Baxter announced the sale of its Kidney Care business to Carlyle for approximately $3.8 billion. The transaction closed in September 2024, creating Vantive as a standalone kidney-care company.[3] Baxter had previously identified Kidney Care as one of its largest operating businesses, with products spanning peritoneal dialysis, hemodialysis, continuous renal replacement therapy and related systems.

Dianeal’s economics are likely characterized by:

• High manufacturing and quality-control requirements.
• Recurring consumables revenue.
• Moderate price competition.
• Significant freight and warehousing expense.
• Exposure to resin, packaging, labor and sterilization costs.
• Contractual pricing with large dialysis operators.
• Working-capital requirements due to inventory and supply continuity.
• Limited product-level selling expense after formulary and protocol adoption.

The divestiture changes the financial interpretation. Under Baxter, Dianeal was part of a diversified medical-products portfolio. Under Vantive, dialysis solutions are core revenue assets. That increases management attention but also concentrates exposure to renal-care reimbursement, production disruptions and customer concentration.

How does DIANEAL compare with competing peritoneal dialysis products?

The principal competitors are Fresenius Medical Care products and other regional or hospital-manufactured peritoneal dialysis solutions. Competition occurs at the platform level rather than solely at the individual bag level.

Product or platform	Company	Main competitive attribute
DIANEAL	Baxter/Vantive	Established peritoneal dialysis solution platform
EXTRANEAL	Baxter/Vantive	Icodextrin-based alternative for longer dwell periods
PHYSIONEAL	Baxter/Vantive	Bicarbonate/lactate-buffered solution platform
Balance	Fresenius Medical Care	Peritoneal dialysis solution portfolio
Stay-Safe and related systems	Fresenius Medical Care	Integrated connection and delivery systems
Regional generic solutions	Various manufacturers	Price and local supply positioning

Dianeal competes through availability, compatibility, clinician familiarity and supply reliability. Clinical differentiation among standard dextrose-based solutions is narrower than in branded therapeutics. The strongest commercial defenses are therefore manufacturing scale, provider relationships, technical support and validated delivery systems.

What patents protect DIANEAL Low Calcium 2.5%?

The principal protection for Dianeal is unlikely to depend on a single active-ingredient patent. Dextrose-based peritoneal dialysis solutions use established ingredients, and the product’s commercial protection is more closely linked to formulation know-how, container systems, manufacturing processes and regulatory approvals.

Potential intellectual-property categories include:

• Solution composition.
• Calcium concentration and electrolyte balance.
• Buffer systems.
• Plastic container construction.
• Multi-chamber or compartmentalized packaging.
• Sterilization methods.
• Connection systems.
• Automated peritoneal dialysis machines.
• Product-use protocols.
• Manufacturing and quality-control methods.

No reliable public basis supports assigning a specific unexpired patent number or Orange Book exclusivity period to this exact presentation without a current FDA product-specific patent record and jurisdictional patent search. The relevant competitive barrier is therefore better described as a manufacturing and regulatory moat than as a conventional composition-of-matter patent estate.

What is the Orange Book status of DIANEAL?

The Orange Book is designed primarily for approved drug products and listed patents or exclusivity associated with those products. Dialysis solutions may not create the same Orange Book patent profile as small-molecule prescription drugs.

For Dianeal, the key regulatory questions are:

• Whether the specific presentation is listed as an NDA product.
• Whether current patents are submitted for that presentation.
• Whether any listed patent covers the formulation, container or method of use.
• Whether the product is marketed under a legacy or amended approval.
• Whether an ANDA pathway is available for a proposed competitor.

A lack of a prominent Orange Book patent listing would not eliminate competitive barriers. A rival manufacturer would still need to establish equivalence, safety, sterility, container compatibility, stability and manufacturing compliance.

Are Paragraph IV challenges likely for Dianeal?

Paragraph IV litigation risk is likely lower than for a high-value oral drug with multiple listed patents. The reasons are structural:

• The product is a sterile solution rather than a conventional tablet or capsule.
• The commercial value is distributed across the broader dialysis platform.
• Manufacturing qualification is expensive.
• Supply reliability is critical.
• Regulatory approval may require extensive product and process comparability.
• A competitor may pursue a regulatory pathway without challenging a large patent estate if no blocking patents are listed.

If an ANDA applicant were to certify that a listed patent is invalid, unenforceable or not infringed, the sponsor could bring a Hatch-Waxman action. The commercial significance of that case would depend on whether the patent covers the exact low-calcium 2.5% presentation, the plastic container, a delivery system or a broader dialysis platform.

No major publicly documented Paragraph IV campaign directed specifically at DIANEAL Low Calcium with Dextrose 2.5% is identified in the available record.

What generic entry risks exist?

Generic entry risk is moderate from a technical perspective but lower from a near-term commercial perspective unless a competitor can obtain reliable manufacturing capacity and provider contracts.

Technical barriers

A competing product must demonstrate:

• Equivalent electrolyte and dextrose composition.
• Appropriate osmolality and pH.
• Sterility.
• Stability throughout shelf life.
• Container integrity.
• Compatibility with dialysis equipment.
• Consistent bag performance.
• Acceptable extractables and leachables profile.
• Validated commercial-scale production.

Commercial barriers

A new supplier must also secure:

• Dialysis-provider contracts.
• Distribution capacity.
• Home-delivery infrastructure.
• Inventory reserves.
• Product liability coverage.
• Pharmacovigilance and complaint-handling systems.
• Physician and nurse familiarity.
• Patient conversion procedures.

The most credible generic-entry scenario is gradual share capture through regional contracts, hospital tenders or supply-constrained markets. A rapid nationwide substitution is less likely because dialysis providers prioritize continuity and system compatibility.

What manufacturing and supply-chain barriers affect Dianeal?

Dianeal is vulnerable to capacity constraints because peritoneal dialysis solutions are bulky, sterile and used in high volume. The product is expensive to transport relative to its ingredient cost. Manufacturing economics depend on plant utilization, bag production, sterilization throughput and regional distribution.

Key barriers include:

Barrier	Commercial effect
Sterile fill and terminal sterilization	Limits qualified production capacity
Plastic bag production	Requires specialized equipment and validated materials
High freight volume	Raises logistics cost
Manufacturing-site changes	Can trigger regulatory filings and customer requalification
Raw-material shortages	Can interrupt production
Quality deviations	May require recalls or supply restrictions
Regional inventory requirements	Increases working capital
Equipment compatibility	Limits substitution

These constraints can support pricing stability even when formulation patents are weak or absent.

What litigation and settlement agreements affect Dianeal?

No major public patent settlement is associated specifically with DIANEAL Low Calcium with Dextrose 2.5% in the available record. Litigation exposure is more likely to arise from:

• Product-quality claims.
• Manufacturing defects.
• Sterility or contamination events.
• Distribution contracts.
• Medical-device compatibility.
• Antitrust disputes involving dialysis-provider purchasing.
• Patent disputes involving dialysis machines, connection systems or broader solution platforms.

Because the product is a medical consumable, litigation risk can affect revenue through recalls, customer loss and regulatory remediation even without a patent judgment.

How does Dianeal compare with hemodialysis products?

Factor	Peritoneal dialysis with Dianeal	In-center hemodialysis
Treatment location	Home	Dialysis center or home
Consumable model	Multiple solution bags per day	Dialyzer, bloodlines and dialysate per session
Infrastructure	Home delivery and training	Center infrastructure and staffing
Revenue pattern	Recurring supply consumption	Recurring procedure and consumable revenue
Switching barrier	Platform and logistics compatibility	Machine and center protocol compatibility
Main growth driver	Home-dialysis adoption	Patient population and center capacity
Supply risk	High-volume sterile fluid availability	Dialysate, filters, machines and staffing

Dianeal benefits when payers and providers seek greater home treatment capacity. It is exposed when patients discontinue peritoneal dialysis because of infection, inadequate clearance, catheter problems, caregiver limitations or modality failure.

What is the geographic coverage and international outlook?

Dianeal has historically been marketed across multiple jurisdictions, subject to local registrations, labeling and reimbursement systems. International demand is strongest where:

• Home dialysis is reimbursed.
• Patients can receive regular supply deliveries.
• Import and distribution systems are reliable.
• Dialysis infrastructure is expanding.
• Providers use standardized Baxter or Vantive equipment.

Emerging-market growth can be substantial but carries currency, pricing and government-tender risk. Developed markets provide more predictable reimbursement but have stronger purchasing pressure and established competition from Fresenius Medical Care.

The Vantive ownership structure may increase focus on international renal-care expansion. It also creates execution risk during the separation from Baxter’s shared services, manufacturing systems and distribution arrangements.

How strong is the Dianeal patent and commercial estate?

The patent estate is likely weaker than that of an innovative pharmaceutical but the commercial estate is stronger than a simple formulation comparison suggests.

Dimension	Assessment
Composition-of-matter protection	Limited for established dextrose/electrolyte formulation
Orange Book exclusivity	Likely limited or presentation-specific
Manufacturing know-how	Meaningful
Sterile production capability	Strong practical barrier
Provider switching costs	Moderate to high
Regulatory complexity	High
Brand value	Established within renal-care channels
Generic substitution risk	Moderate
Supply disruption risk	Material
Long-term demand	Stable to growing with home dialysis

The central investment question is not whether a competitor can reproduce the solution chemistry. It is whether the competitor can supply a clinically acceptable product at scale, maintain uninterrupted availability and win contracts against an established platform.

What are the main financial risks?

The principal risks to Dianeal-related revenue are:

1. Manufacturing interruption or recall.
2. Loss of large dialysis-provider contracts.
3. Pricing pressure from Fresenius Medical Care or regional suppliers.
4. Reduced peritoneal dialysis adoption relative to hemodialysis.
5. Patient attrition from peritoneal dialysis.
6. Higher freight and packaging costs.
7. Regulatory remediation.
8. Delays in Vantive’s operational separation.
9. Currency and tender-price pressure outside the United States.
10. Increased adoption of alternative dialysis solutions or modalities.

Revenue is likely defensive but not immune to volatility. A plant disruption can produce a sharp temporary revenue decline and customer migration. Conversely, supply scarcity can support price realization for available inventory but may accelerate competitor qualification.

Key Takeaways

• DIANEAL Low Calcium with Dextrose 2.5% is a mature peritoneal dialysis consumable with recurring utilization.
• Product-level revenue is not publicly disclosed.
• Its financial performance is best assessed through Baxter’s former Kidney Care business and Vantive’s post-2024 standalone results.
• The product’s main protection is manufacturing scale, regulatory compliance, supply reliability and provider integration, not a conventional high-value pharmaceutical patent.
• Paragraph IV risk appears lower than for patented oral drugs, but sterile-equivalence and commercial qualification barriers remain significant.
• Demand is supported by end-stage kidney disease prevalence and home-dialysis adoption.
• Fresenius Medical Care is the principal global competitor.
• The most material downside risk is supply interruption or customer displacement, not ordinary generic price erosion.
• Vantive’s ownership transition may improve strategic focus while increasing separation and execution risk.

FAQs About DIANEAL Low Calcium 2.5%

Is DIANEAL Low Calcium 2.5% still commercially relevant?

Yes. It remains relevant as a standard dextrose-based peritoneal dialysis solution, although demand depends on continued use of peritoneal dialysis and the availability of alternative formulations.

Does Dianeal have a composition-of-matter patent?

The established dextrose-electrolyte formulation is unlikely to have the type of long-duration composition-of-matter protection associated with innovative small-molecule drugs. Commercial protection is more dependent on manufacturing and regulatory barriers.

Who owns the Dianeal business?

The kidney-care business formerly owned by Baxter was sold to Carlyle and operates as Vantive following the 2024 transaction.

Can a hospital switch from Dianeal to another peritoneal dialysis solution?

Potentially, but substitution requires review of formulation, equipment compatibility, clinical protocols, supply reliability, labeling and provider procedures.

Is Dianeal revenue exposed to biosimilar competition?

No. Dianeal is a sterile dialysis solution, not a biologic. Biosimilar regulation does not govern its primary competitive pathway. Its competitive risks involve generic-equivalent solutions, dialysis platforms, manufacturing capacity and provider contracts.

References

1. U.S. Department of Health and Human Services. (2019). Advancing American kidney health. https://aspe.hhs.gov
2. United States Renal Data System. (2023). 2023 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases. https://usrds-adr.niddk.nih.gov
3. Baxter International Inc. (2024). Baxter completes sale of Kidney Care business to Carlyle. https://www.baxter.com
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA and Orange Book resources. https://www.fda.gov
5. Vantive. (2024). Kidney care products and solutions. https://www.vantive.com